Future of the Lung Cancer Liquid Biopsy Market: Strategic Analysis and Forecast to 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Lung Cancer Liquid Biopsy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of lung cancer liquid biopsy has seen remarkable growth in the past few years. Forecasts suggest a surge from $0.95 billion in 2024 to $1.12 billion in 2025, representing a compound annual growth rate (CAGR) of 17.0%. Factors contributing to this growth during the historic period include the growing prevalence of lung disorders caused by smoking and pollution, increased use of liquid biopsy in monitoring treatment, significant boost in oncology-related research and development, a rising demand for rapid, cost-effective diagnostics, and an increase in clinical trials.

Lung Cancer Liquid Biopsy Market Size Forecast: What's the Projected Valuation by 2029?
In the upcoming years, the lung cancer liquid biopsy market is predicted to experience a swift expansion. The market is projected to burgeon to $2.08 billion by 2029, with a compound annual growth rate (CAGR) of 16.8%. The growth anticipated during the forecasted period can be credited to factors such as the escalating prevalence of lung cancer, an increase in the demand for non-invasive diagnostic procedures, the progressive adoption of individualized medicine, enhanced awareness of early cancer detection, and a growing older population vulnerable to cancer. The forecast period is expected to showcase major trends including progress in circulating tumor dna (ctdna) analysis methods, technological evolution in exosome-centered liquid biopsy, progress in microfluidics for the isolation of circulating tumor cells, the incorporation of artificial intelligence and machine learning for biomarker interpretation, and technological breakthroughs that enable multiplex biomarker analysis.

View the full report here:
https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

What Are the Drivers Transforming the Lung Cancer Liquid Biopsy Market?
The escalating prevalence of lung cancer is anticipated to boost the lung cancer liquid biopsy market's expansion. Lung cancer is a malady marked by the unchecked proliferation of irregular cells in the lungs, commonly a result of smoking and environmental factors. The incidence of lung cancer is rising due to sustained tobacco consumption, because smoking subjects the lungs to cancer-causing substances that instigate irregular cell growth. Lung cancer liquid biopsy aids by identifying cancer-related genetic alterations and tumor DNA via a blood sample, thus facilitating early detection, choosing adequate treatment, and tracking illness advancement or response to treatment. For instance, it was reported by The American Cancer Society, a non-profit organization devoted to eradicating cancer, that as of January 1, 2022, 654,620 individuals in the U.S. had a history of lung cancer, with a significant number living with metastatic disease. About 80% were aged 65 or older, and 55% were diagnosed during the previous five years due to low survival rates. Thus, the rising prevalence of lung cancer is causing increased growth in the lung cancer liquid biopsy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

What Long-Term Trends Will Define the Future of the Lung Cancer Liquid Biopsy Market?
The lung cancer liquid biopsy market's dominant firms are paying attention to technological enhancements such as blood-based lung cancer screening tests, with the hope of improving early detection, diagnostic accuracy, and real-time, non-invasive monitoring of tumor development and treatment efficacy. The non-invasive blood-based lung cancer screening test works by examining biomarkers in the blood to detect lung cancer at an early stage. For example, in October 2023, DELFI Diagnostics Inc., a biotech company from the US, introduced FirstLook Lung, a blood-based liquid biopsy test crafted to assist in premature lung cancer detection. This test uses fragmentomics to detect early stages of lung cancer with a high degree of sensitivity and a 99.8% negative predictive value, making it a feasible and accessible initial step for people at risk. The goal is to enhance early detection, boost screening frequency, and efficiently utilize further imaging resources for those who stand the highest chance of benefitting.

Which Segments in the Lung Cancer Liquid Biopsy Market Offer the Most Profit Potential?
The lung cancer liquid biopsy market covered in this report is segmented -

1) By Product: Instruments, Sconsumables Kits And Reagents, Software And Services
2) By Technology: Multi Gene-Parallel Analysis (Ngs), Single Gene Analysis (Pcr Microarrays)
3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers
4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications
5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centres, Other End Users

Subsegments:
1) By Instruments: Pcr Instruments, Microarray Instruments, Next-Generation Sequencing (Ngs) Instruments
2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents
3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

Which Firms Dominate the Lung Cancer Liquid Biopsy Market by Market Share and Revenue in 2025?
Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Which Regions Offer the Highest Growth Potential in the Lung Cancer Liquid Biopsy Market?
North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24593

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.